Byrd, J. C. Et Al. 2021. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.31 , 3441-3454.

Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., ... O'Brien, S.(2021). Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.31, 3441-3454.

Byrd, John Et Al. "Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.31, 3441-3454, 2021

Byrd, John C. Et Al. "Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.31, pp.3441-3454, 2021

Byrd, J. C. Et Al. (2021) . "Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.31, pp.3441-3454.

@article{article, author={John C. Byrd Et Al. }, title={Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021, pages={3441-3454} }